You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

furmonertinib

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Double-dose Furmonertinib in Treatment of Slow

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Furmonertinib
  • (no location specified)
Oct 31, 2023

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Furmonertinib
  • (no location specified)
Aug 10, 2023

Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

Recruiting
  • Lung Adenocarcinoma Stage III
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Aug 13, 2022

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Furmonertinib
  • Glendale, California
  • +12 more
Feb 2, 2023

Furmonertinib, EGFR-mutation, NSCLC Trial in Beijing (Furmonertinib)

Recruiting
  • Furmonertinib
  • +3 more
  • Furmonertinib
  • Beijing, China
    Ethics Committee
Jul 15, 2022

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • Furmonertinib
  • (no location specified)
Jul 17, 2022

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Furmonertinib
  • (no location specified)
Jul 5, 2022

NSCLC Trial in Changsha (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Furmonertinib
  • Changsha, Hunan, China
    Hunan Cancer hospital
May 19, 2022

NSCLC Trial (Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Recruiting
  • Non-small Cell Lung Cancer
  • Furmonertinib
  • +2 more
  • Changchun, China
  • +25 more
Aug 26, 2022

NSCLC Trial in Shanghai (IN10018, Furmonertinib)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 8, 2023

Non-Small-Cell Lung Cancer Trial in Shanghai (Furmonertinib, Anlotinib)

Recruiting
  • Non-Small-Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Oct 14, 2021

Lung Adenocarcinoma Trial (Furmonertinib)

Not yet recruiting
  • Lung Adenocarcinoma
  • Furmonertinib
  • (no location specified)
Jul 8, 2021

NSCLC, Oligoprogressive Trial in Guangzhou (Furmonertinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Oligoprogressive
  • Furmonertinib
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Jul 10, 2021

NSCLC, EGF-R Positive NSCLC Trial in Shanghai (Furmonertinib)

Recruiting
  • NSCLC
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Furmonertinib
  • Shanghai, Shanghai, China
    Shanghai General Hospital
Jan 12, 2022

Adenocarcinoma of Lung Trial in Beijing (Furmonertinib)

Not yet recruiting
  • Adenocarcinoma of Lung
  • Furmonertinib
  • Beijing, China
    Peking University People's Hospital
Oct 3, 2021

Multiple Primary Lung Cancers Trial in China (furmonertinib, Placebo)

Recruiting
  • Multiple Primary Lung Cancers
  • furmonertinib
  • Placebo
  • Fuzhou, Fujian, China
  • +5 more
Oct 4, 2021